profit from every $100 of sales.
$0$100
Danaher
$233.02+0.37% today
+5.3% in 1 year
1-year low $161.911-year high $242.05
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $45.36 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Danaher sold, what it kept, and what it did with the cash.
Sales went from $26.6 billion in 2022 to $24.6 billion in 2025, with $3.61 billion of profit last year.
SalesProfit
Danaher handed back 75% of the cash it generated last year.
Buybacks $3.1B$878M
Free cash flow 2025$5.3B
Bought back its own shares$3.1B
Paid as dividends$878M
Cash vs. debt$4.6B vs. $19.7B
Danaher vs. similar companies
Danaher grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Danaher | 45.4× · Expensive | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Waters | 140.8× · Very expensive | ||
 WuXi AppTec | 25.8× · Fair price | ||
 Lonza Group | No profit yet |
Compare Danaher with Ametek · Keysight Technologies · Eli Lilly
AI analysis
An AI analyst reads Danaher's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 22,284 | 24,802 | 26,643 | 23,890 | 23,875 | 24,568 | |
| 12,475 | 15,239 | 16,188 | 14,034 | 14,206 | 14,523 | |
| 4,231 | 6,377 | 7,536 | 5,202 | 4,863 | 4,690 | |
| 6,545 | 8,804 | 9,482 | 7,496 | 7,276 | 6,945 | |
| 3,646 | 6,433 | 7,209 | 4,764 | 3,899 | 3,614 | |
| 4.89 | 8.61 | 9.66 | 6.38 | 5.29 | 5.05 | |
| 56.0% | 61.4% | 60.8% | 58.7% | 59.5% | 59.1% | |
| 19.0% | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% | |
| 16.4% | 25.9% | 27.1% | 19.9% | 16.3% | 14.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 76,161 | 83,184 | 84,350 | 84,488 | 77,542 | 83,464 |
| Cash | 6,035 | 2,586 | 5,995 | 5,864 | 2,078 | 4,615 |
| Total debt | 21,989 | 23,065 | 20,616 | 19,536 | 17,146 | 19,696 |
| Total liabilities | – | – | 34,260 | 30,998 | 27,992 | 30,923 |
| 39,766 | 45,167 | 50,082 | 53,486 | 49,543 | 52,534 | |
| 719 | 737 | 737 | 743 | 737 | 716 | |
| 6.1% | 7.8% | 8.2% | 5.8% | 5.8% | 4.9% | |
| 9.2% | 14.2% | 14.4% | 8.9% | 7.9% | 6.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 6,208 | 8,358 | 8,519 | 7,164 | 6,688 | 6,416 | |
| 791 | 1,240 | 1,118 | 1,383 | 1,392 | 1,156 | |
| 5,417 | 7,118 | 7,401 | 5,781 | 5,296 | 5,260 | |
| Dividends paid | 615 | 742 | 818 | 1,248 | 768 | 878 |
| – | – | 0 | 0 | 5,979 | 3,088 | |
| 187 | 184 | 295 | 306 | 288 | 298 |
Valuation
- 45.4×
- 27.6×
- 70.22
- 3.1×
- 6.7×
- 31.2×
- 25.8×
- 3.2%
- 2.2%
- 0.8%
Profitability
- 59.1%
- 19.1%
- 14.7%
- 27.0%
- 5.0%
- 6.3%
- 7.1%
- 4.4%
- 6.8%
- 6.5%
Growth
- +2.0%
- +0.6%
- −0.7%
- +14.9%
- −1.0%
Financial health
- 2.2×
- 0.37
- 22.1%
- 17.0×
- 1.87
- 1.52
- 0.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 49%of 946
Top 26%of 872
Bottom 27%of 565
Bottom 19%of 867
Top 33%of 986
What analysts expect
- Average price target
- $247.00
- Range
- $205.00 – $270.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 21, 2026 | 2.06 | 1.94 | +6.2% |
| Jan 28, 2026 | 2.23 | 2.16 | +3.2% |
| Oct 21, 2025 | 1.89 | 1.72 | +9.9% |
| Jul 22, 2025 | 1.80 | 1.64 | +9.8% |
| Apr 22, 2025 | 1.88 | 1.63 | +15.3% |
| Jan 29, 2025 | 2.14 | 2.14 | +0.0% |
| Oct 22, 2024 | 1.71 | 1.57 | +8.9% |
| Jul 23, 2024 | 1.72 | 1.57 | +9.6% |
0.8%of the share price, paid each year
On $1,000 invested$8a year at today's yield, before tax
+14.9%2020 to 2025
Raised8 yearsin a row, in our data
Paid per share, each year
$0.50 in 2015 → $1.28 in 2025
How safe it looks
24.3% of its profit
Room to growStretchedMore than it earns: 16.7%
News
What Danaher Stock's AI Lab Push Means For ShareholdersYahoo Finance · Oct 17, 2026Danaher Collaborates with NVIDIA to Advance Autonomous ScienceYahoo Finance · Oct 14, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
37No pass
Philip Fisher
42No pass
Peter Lynch
18No pass
Joel Greenblatt
3No pass
Charlie Munger
41No pass
Terry Smith
40No pass
Questions about Danaher
Is Danaher a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Danaher AI analysis
What does Danaher do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. It is in Diagnostics & Research, based in Washington, DC, United States, with 58,000 employees.
Does Danaher pay a dividend?
Yes. At today's price the dividend is 0.8% a year, about 24% of its yearly profit. In 2025 it paid out $878 million in dividends.
Is Danaher stock halal?
Yes. Danaher passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has Danaher stock done over the past year?
Up 5.3% over the past twelve months, to $233.02. It traded between $161.91 and $242.05 and is 3.7% below its high.
Who are Danaher's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Waters, WuXi AppTec and Lonza Group. The peers table on this page compares their profit, growth and price with Danaher's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.